首页> 美国卫生研究院文献>Journal of Health Population and Nutrition >Post-kala-azar Dermal Leishmaniasis with Mucosal Involvement: An Unusual Case Presentation including Successful Treatment with Miltefosine
【2h】

Post-kala-azar Dermal Leishmaniasis with Mucosal Involvement: An Unusual Case Presentation including Successful Treatment with Miltefosine

机译:黑热病后皮肤利什曼病伴粘膜受累:一个不寻常的病例报告包括米替福辛成功治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Post-kala-azar dermal leishmaniasis (PKDL) is a dermatologic manifestation that usually occurs after visceral leishmaniasis (VL) caused by Leishmania donovani. It is characterized by hypopigmented patches, a macular or maculopapular rash and nodular skin lesions on the body surface. Involvement of the mucosae is very rare and unusual in PKDL. We report a case of PKDL that presented with polymorphic skin lesions, along with involvement of peri-oral mucosa and tongue from an endemic area for kala-azar in Bangladesh. In the absence of a definite past history of kala-azar, a clinical suspicion for PKDL was confirmed by positive rapid serological tests against two recombinant (rK39 and rK28) leishmanial antigens, demonstration of Leishmania donovani (LD) body in the slit skin smear, and isolation of promastigotes by culture from a nodular lesion. The patient was treated with oral Miltefosine for three consecutive months and showed significant clinical improvement as demonstrated by a negative slit skin smear at two months after initiation of therapy. We report this case as an unusual presentation of mucosal involvement in PKDL and subsequent treatment success with Miltefosine.
机译:黑热病后皮肤利什曼病(PKDL)是一种皮肤病学表现,通常发生在由利什曼原虫donovani引起的内脏利什曼病(VL)之后。其特征是色素沉着斑块,黄斑或斑丘疹和体表结节性皮肤病变。在PKDL中,粘膜的参与非常罕见且不常见。我们报告了一个PKDL病例,该病例表现出多态性皮肤病变,以及孟加拉国黑热病流行地区的口腔周围粘膜和舌头受累。在没有明确的黑热病病史的情况下,通过针对两种重组(rK39和rK28)利什曼原虫抗原的快速血清学检测阳性,证实了PKDL的临床怀疑,在狭缝皮肤涂片中显示了利什曼原虫donovani(LD)体,从结节性病变中分离培养前鞭毛体。该患者连续三个月接受口服米替福辛治疗,并在治疗开始后两个月出现狭缝皮肤涂片阴性,显示出明显的临床改善。我们将此病例报告为黏膜参与PKDL和随后用Miltefosine成功治疗的异常表现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号